α- and β-Adrenoceptors: From the Gene to the Clinic. 2. Structure-Activity Relationships and Therapeutic Applications

Journal of Medicinal Chemistry

Volumn 38, Issue 19, 1995, Pages 3681-3716

  Ruffolo, Robert R ^a   Bondinell, William ^a   Hieble, J Paul ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; ARALKYLAMINE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUNAZOSIN; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DOXAZOSIN; FORMOTEROL; GUANIDINE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; IMIDAZOLINE DERIVATIVE; IMIPRAMINE; MIDAGLIZOLE; PHENETHYLAMINE DERIVATIVE; PHENOXYPROPANOLAMINE DERIVATIVE; PRAZOSIN; QUINAZOLINE DERIVATIVE; RECEPTOR SUBTYPE; SALBUTAMOL; TAMSULOSIN; TERAZOSIN; UNINDEXED DRUG; XAMOTEROL; YOHIMBINE DERIVATIVE;

ANALGESIA; ANIMAL CELL; ASTHMA; BINDING AFFINITY; BRAIN ISCHEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NORMAL HUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; REVIEW; SEDATION; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMAL; HUMAN; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029113808     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00019a001     Document Type: Article

References (179)

1. Pratesi, P.; Grana, E. Structure and activity at adrenergic receptors of catecholamines and certain related compounds. Adv. Drug. Res. 1965, 2, 127-142.
2. Hieble, J. P. Structure-activity relationships for activation and blockade of β-adrenoceptors. In: ß-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology, Ruffolo, R. R., Jr., Ed.; Karger: Basel, 1991; Vol. 7, pp 105-172.
3. 2-adrenoceptor agonist, salmeterol. Br. J. Pharmacol. 1987, 92, 591.
4. Johansson, L. H.; Persson, H.; Rosengren, E. Adrenoceptor selectivity in four series of β-adrenoceptor agonists. Eur. J. Pharmacol. 1986, 130, 97-103.
5. Michel, M. C.; Buscher, R.; Kerker, J.; Kraneis, H.; Erdbrugger, W.; Brodde, O.-E. ai-Adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Naunyn-Schmeide-berg’s Arch. Pharmacol. 1993, 348, 385-395.
6. Minneman, K. P.; Theroux, T. L.; Hollinger, S.; Han, C.; Esbenshade, T. A. Selectivity of agonists for cloned di-adrenergic receptor subtypes. Mol. Pharmacol. 1994, 46, 929-936.
7. Flavahan, N. A.; Vanhoutte, P. M. a-Adrenoceptor subclassification in vascular smooth muscle. Trends Pharmacol. Sci. 1986, 7, 347-349.
8. Arch, J. R.; Ainsworth, A. T.; Cawthome, M. A.; Piercy, V.; Sennitt, M. V.; Thod, V. E.; Wilson, C.; Wilson, S. Atypical β-adrenoceptors on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309, 163-165.
9. Bloom, J. D.; Dutia, M. D.; Johnson, B. D.; Wissner, A.; Burns, M. G.; Largis, E. E.; Dolan, J. A.; Claus, T. H. Disodium (R, R)- 5-2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1, 3-ben- zodioxole-2, 2-dicarboxy late (CL 316, 243), a potentβ-adrenergic agonist virtually specific for receptors. A promising antidiabetic and antiobesity agent. J. Med. Chem. 1992, 35, 3081-3084.
10. Cawthome, M. A. Thermogenic drugs. The potential of selective β-adrenoceptor agonists as anti-obesity drugs. In Progress in Obesity Research; Oomura, Y., et al., Eds.; John Libbey & Co. Ltd.: London, 1990; pp 567-574.
11. Bianchetti, A.; Manara, L. In vitro inhibition of intestinal motility by phenylethanolamintetralines: Evidence of atypical adrenoceptors in rat colon. Br. J. Pharmacol. 1990, 100, 831-839.
12. Pietri-Rouxel, F.; Drumare, M. F.; Strosberg, A. D. Pharmacological characteristics of adrenergic receptors. Pharmacol. Commun. 1995, 6, 229-236.
13. Hieble, J. P.; Nelson, S. H.; Steinsland, O. S. Neuronal dopamine receptors of the rabbit ear artery: pharmacological characterization of the receptor. J. Auton. Pharm. 1985, 5, 115-124.
14. Jim, K. F.; Macia, R. A.; Matthews, W. D. An evaluation of the ability of a series of full alpha-1 adrenoceptor agonists to release internal calcium in venous smooth muscle. J. Pharmacol. Exp. Ther. 1985, 235, 377-381.
15. Ruffolo, R. R., Jr.; Waddell, J. E. Aromatic and benzylic hydroxyl substitution of imidazolines and phenethylamines: differences in activity at a. i- and X2-adrenergic receptors. J. Pharmacol. Exp. Ther. 1983, 224, 559-566.
16. Gorczynski, R. J.; Anderson, W. G. N-aralkyl substitution of 2-amino-5, 6- and -6, 7-dihydroxy-1, 2, 3, 4-tetrahydronaphthalenes. I. Cardiac and pressor/depressor activities. J. Med. Chem. 1981, 24, 835-839.
17. Delgado, A.; Mauleon, D.; Roseli, G.; Granados, R. Synthesis and adrenergic properties of cyclic analogues of methoxamine: 2-amino-1, 2, 3, 4-tetrahydro-1-naphthalenols. Eur. J. Med. Chem. 1988, 23, 31.
18. Hieble, J. P.; Sarau, H.; Foley, J.; DeMarinis, R. M.; Pendleton, R. G. Comparison of central and peripheral alphai-adrenoceptors. Naunyn-Schmeideberg’s Arch. Pharmacol. 1982, 318, 267.
19. DeMarinis, R. M.; Hieble, J. P. SK&F1-89748-A. A potent and selective agonist at alphaj-adrenergic receptors. J. Med. Chem. 1983, 26, 1215-1218.
20. Holz, W. C.; Hieble, J. P.; Gill, C. A.; DeMarinis, R. M.; Pendleton, R. G. Alp/ia-adrenergic agents. 3. Behavioral effects of 2-aminotetralins. Psyckopharm. 1982, 77, 259-265.
21. Nozulak, J.; Vigouret, J. M.; Jaton, A. L.; Hoftnann, A.; Dravid, A. R.; Weber, H. P.; Kalkman, H. O.; Walkinshaw, M. D. Centrally acting (Xi-adrenoceptor agonists based on hexa- hydroanphth[2, 3-fc]-1, 4-oxazines and octahydrobenzo[g]quinolines. J. Med. Chem. 1992, 35, 480-489.
22. Weinstock, J.; Hieble, J. P.; Wilson, J. W. The chemistry and pharmacology of 3-benzazepine derivatives. Drugs Future 1985, 10, 645-697.
23. Daly, R. N.; Sulpizio, A. C.; Levitt, B.; DeMarinis, R. M.; Regan, J. W.; Ruffolo, R. R.; Hieble, J. P. Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines. J. Pharmacol. Exp. Ther. 1988, 247, 122-128.
24. Kaiser, C.; Jen, T.; Garvey, E.; Bowen, W. D. Adrenergic agents. 4. Substituted phenoxypropanolamine derivatives as potential β-adrenergic agonists. J. Med. Chem. 1977, 20, 687-692.
25. Hieble, J. P.; Ruffolo, R. R., Jr. Therapeutic applications of agents interacting with β-adrenoceptors. In ß-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology, Ruffolo, R. R., Jr.; Ed.; Karger: Basel, 1991; Vol. 7, pp 210-235.
26. Uchida, W.; Shibasaki, K; Asano, M.; Takenaka, T. Antianginal effects ofYM-16151-4 in various experimental angina models. J. Cardiovasc. Pharmacol. 1993, 21, 701-708.
27. Shibasaki, K; Uchida, W.; Shirai, Y.; Inagaki, O.; Asano, M.; Takenaka, T. Pharmacological properties of YM-15430-1, a 1, 4- dihydropyridine derivative with βi-adrenoceptor blocking activity. Arch. Int. Pharmacodyn. 1994, 328, 213-224.
28. Allan, G.; Cambridge, D.; Hardy, G. W.; Folienfant, M. J. BW A575C, a chemically novel agent with angiotensin converting enzyme inhibitor and β-adrenoceptor blocking properties. Br. J. Pharmacol. 1987, 90, 609-615.
29. Argentieri, T. M.; Troy, H. H.; Carroll, M. S.; Doroshuk, C. M.; Sullivan, M. E. Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with adrenergic blocking properties. J. Cardiovasc. Pharmacol. 1993, 21, 647-655.
30. 3) β-adrenoceptors. Pharmacol. Commun. 1995, 6, 251-258.
31. Langin, D.; Portillo, M. P.; Saulnier-Blanche, J.; Lafontan, M. Coexistence of three β-adrenoceptor subtypes in white fat cells of various mammalian species. Eur. J. Pharmacol. 1991, 199, 291-301.
32. Timmermans, P. B. M. W. M.; van Zwieten, P. A. a2-Adrenoceptor: Classification, localization, mechanisms and targets for drugs. J. Med. Chem. 1982, 25, 1389-1401.
33. Young, P.; Berge, J.; Chapman, H.; Cawthome, M. A. Novel (12- adrenoceptor antagonists show selectivity for a. 2A- and 0 (2b- adrenoceptor subtypes. Eur. J. Pharmacol. 1989, 168, 381-386.
34. Gleason, M. M.; Hieble, J. P. Ability of SK&F 104078 and SK&F 104856 to identify alpha-2 adrenoceptor subtypes in NCB20 cells and guinea pig lung. J. Pharmacol. Exp. Ther. 1991, 259, 1124-1132.
35. Michel, A. D.; Loury, D. N.; Whiting, R. L. Assessment of imiloxan as a selective a. 2B-adrenoceptor antagonist. Br. J. Pharmacol. 1990, 99, 560-564.
36. Hieble, J. P.; Ruffolo, R. R., Jr. Possible Structural and Functional Relationships Between Imidazoline Receptors and (X2- Adrenoceptors. Proc. N. Y. Acad. Sci. 1995, in press.
37. 2-adrenoceptors. Br. J. Pharmacol. 1993, 110, 1635-1639.
38. Jarrott, B.; Summers, R. J.; Culvenor, A. J.; Louis, W. J. Characterization of a-adrenoceptors in rat and guinea-pig tissues using radiolabelled agonists and antagonists. Circ. Res. 1980, 46 (Suppl. I), 115-120.
39. Savoia, J.; Ruskoaho, H.; Puurunen, J. e. Evidence for medeto- midine as a selective and potent agonist at a2-adrenoceptors. J. Auton. Pharmacol. 1986, 5, 275-284.
40. Noyer, M.; de Leveleye, F.; Vauquelin, G.; Gobert, J.; Wulfert, E. Mivazerol, a novel compound with high specificity for 0. 2- adrenergic receptors: Binding studies on different human and rat membrane preparations. Neurochem. Int. 1994, 24, 21-229.
41. Wright, R. A.; Decroly, P.; Kharkevitch, T.; Oliver, M. F. Exercise tolerance in angina is improved by mivazerol an o adrenoceptor agonist. Cardiovasc. Drugs Ther. 1993, 7, 929-934.
42. Hieble, J. P.; Naselsky, D. P. Determination of a2-adrenoceptor subtype selectivity in tissue homogenates and cell lines. Pharmacologist 1993, 35, 166.
43. Kyncyl, J. J.; Horrom, B. W., Nordeen, C. W.; Juberg, E. N.; Bush, E. N. Terazosin enantiomers: alpha adrenoceptor interaction and antihypertensive properties. Eur. J. Pharmacol. 1990, 183, 828.
44. Meretyk, S.; Tang, R.; Shapiro, E.; Kyncyl, J. J.; Lepor, H. Alpha-1 adrenoceptor properties of terazosin and its enantiomers in the human prostate and canine brain. Prostate 1992, 20, 159-165.
45. Forray, C.; Bard, J. A.; Wetzel, J. M.; Chiu, G.; Shapiro, E.; Tang, R.; Lepor, H.; Hartig, P. R.; Weinshank, R. L.; Branchek, T. A.; Gluchowski, C. The ai-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human aie subtype. Mol. Pharmacol. 1994, 45, 703-708.
46. Vizi, E. S.; Toth, I.; Somogyi, G. T.; Szabo, L.; Harsin, L. G.; Szantay, C. Berbanes: a new class of selective X2-adrenoceptor antagonists. J. Med. Chem. 1987, 30, 1355-1359.
47. Bill, S. J.; Boniface, A.; Haroun, F.; McAdams, R. P.; Lattimer, N.; Rhodes, K. F. Some pharmacological properties of WY 27127 a more selective alpha2: alphai-adrenoceptor antagonist than idazoxan in vitro. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1986, 334, 418-422.
48. Lattimer, N.; McAdams, R. P.; Rhodes, K. F.; Sharma, S.; Turner, S. J.; Waterfall, J. F. Alpha2-adrenoceptor antagonism and other pharmacological antagonist properties of some substituted ben- zoquinolizines and yohimbine in vitro. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1984, 327, 312-318.
49. Pettibone, D. J.; Clineschmidt, B. V.; Lotti, V. J.; Martin, G. E.; Huff, J. R.; Randall, W. C.; Vacca, J.; Baldwin, J. J. L-654, 284, a new potent and selective (X2-adrenoceptor antagonist. Naunyn- Schmideberg’s Arch. Pharmacol. 1986, 333, 110-116.
50. Clineschmidt, B. V.; Pettibone, D. J.; Lotti, V. J. A peripherally acting alpha-2 adrenoceptor antagonists: L-659, 066. J. Pharmacol. Exp. Ther. 1988, 245, 32-40.
51. Clark, R. D.; Repke, D. B.; Kilpatrick, A. T.; Brown, C. M.; McKinnon, A. C.; Clague, R. U.; Spedding, M. (8aa, 12aa, 13aa)- 5, 8, 8a, 9, 10, ll, 12, 12a, 13, 13a-Decahydro-3-methoxy-12-(methyl- sulfonyl)-6H-isoquino[2, l-g][1, 6]naphthyridine, a potent and highly selective (12-adrenoceptor antagonist. J. Med. Chem. 1989, 32, 2034-2036.
52. Piascik, M. T.; Butler, B. T.; Pruitt, T. A.; Kusiak, J. W. Agonist interaction with alkylation-sensitive and resistant alpha-1 adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 1990, 254, 982-991.
53. Mante, S.; Minneman, K. P. The alkylating prazosin analog SZL 49 inactivates both au- and aiB-adrenoceptors. Eur. J. Pharmacol. (Mol. Pharmacol.) 1991, 208, 113-117.
54. Hoo, K. H.; Kwan, C. Y.; Daniel, E. E. Investigation of ai- adrenoceptor subtypes in canine aorta, using alkylating agents. Can. J. Physiol. Pharmacol. 1994, 72, 97-103.
55. Homburger, V.; Gozlan, H.; Bouhelal, R.; Lucas, M.; Bockaert, J. Irreversible blockade of adrenergic receptors with a bro- moacetyl derivative of pindolol. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1985, 328, 270-287.
56. Minneman, K. P.; Mowry, C. B. Interactions of putatively irreversible antagonist with ßi- and / adrenergic receptors. Biochem. Pharmacol. 1986, 35, 857-864.
57. Ng, N. L.; Malta, E. Organ-bath studies using the irreversible β-adrenoceptor antagonist bromoacetylalprenololmenthane (BAAM). J. Auton. Pharmacol. 1989, 9, 189-200.
58. Regan, J. W.; DeMarinis, R. M.; Lefkowitz, R. J. Arylazide photoaffinity probe for a2-adrenoceptors. Biochem. Pharmacol. 1985, 34, 3667-3672.
59. Renaud, A.; Nishino, S.; Dement, W. C.; Guilleminault, C.; Mignot, E. Effects of SDZ NVI-085, a putative subtype-selective ai-agonist, on canine cateplexy, a disorder of rapid eye movement sleep. Eur. J. Pharmacol. 1991, 205, 11-16.
60. Eltze, M.; Boer, R. The adrenoceptor agonist, SDZ NVI 085, discriminates between au- and ais-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat. Eur. J. Pharmacol. 1992, 224, 125-136.
61. Buscher, R.; Insel, P. A.; Michel, M. C. Is SDZ NVI-085 an ai- adrenergic subtype-selective agonist. Life Sci. 1994, 54, 999-1007.
62. Szabo, B.; Urban, R.; Starke, K. Sympathoinhibition by rilmeni- dine in conscious rabbits: involvement of a2-adrenoceptors. Naunyn-Schmeideberg’s Arch. Pharmacol. 1993, 348, 593-600.
63. Urban, R.; Szabo, B.; Starke, K. Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors? J. Pharmacol. Exp. Ther. 1994, 270, 572-578.
64. Ernsberger, P.; Damon, T. H.; Graff, L. M.; Schaffer, S. G.; Christen, M. O. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for Ii-imidazoline sites. J. Pharmacol. Exp. Ther. 1993, 264, 172-182.
65. Gluchowski, C.; Garst, M. E.; Burke, J. A.; Wheeler, L. A. Methods for using (2-Imidazolin-2ylamino) quinoxaline derivatives. International Patents Application, No. WO 93/13771, July 22, 1993.
66. Munk, S. A.; Gluchowski, C.; Dolby, L.; Wong, H.; Burke, J.; Kharlamb, A.; Manlapaz, C.; Padillo, E.; Rodgers, D.; Ohta, B.; Wheeler, L.; Garst, M. Analogs of UK 14, 304 as a2-adrenoceptor agonists. Twist and agent polarity as design elements. Bioorg. Med. Chem. Lett. 1994, 4, 459-462.
67. Hieble, J. P.; Sulpizio, A. C.; Ashton, D. A.; Naselsky, D. P.; McCafferty, G. P.; Gluchowski, C. AGN 190851, a potent, peripherally acting a2-adrenoceptor agonist. Pharmacologist 1991, 33, 214.
68. 3H] RX 821002 and distribution along the villus-crypt axis. J. Pharmacol. Exp. Ther. 1990, 254, 888-893.
69. Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D. P.; Bergsma, D. J.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. Ree 15/2739 (SB 216469), a novel prostate selective ai-adrenoceptor antagonist. Pharmacol. Commun. 1995, 6, 79-86.
70. Testa, R.; Sironi, G.; Colombo, D.; Greto, D.; Leonardi, A. Ree 15/2739, a new ai-antagonist selective for the lower urinary tract: In vivo studies. Neurology Urodynamics 1994, 13, 471-473.
71. George, P.; Borg, F.; O’Connor, S.; Lechaire, J.; Arbilla, S.; Pimoule, C.; Graham, D.; Wedzikowsky, T.; Langer, S. Urose- lective ai-adrenoceptor antagonists for the treatment of benign prostatic hypertrophy. Eur. J. Med. Chem. 1995, 30 (Suppl.), 2995-3105.
72. Weinberg, D. H.; Trivedi, P.; Tan, C. P.; Mitra, S.; Perkins-Barrow, A.; Borkowski, D.; Strader, C. D.; Bayne, M. Cloning, expression and characterization of human a-adrenergic receptors au, aïs and aie- Biochem. Biophys. Res. Commun. 1994, 20, 1296-1304.
73. Gluchowski, C.; Wetzel, J. M.; Chiu, G.; Marzabadi, M. R.; Wong, W. C.; Nagarathnam, D. Dihydropyridines and new uses thereof. International Patents Application, No. WO 94/22829, October 13, 1994.
74. Gluchowski, C.; Forray, C.; Chiu, G.; Branchek, T. A.; Wetzel, J.; Hartig, P. R. The use of alpha-lC specific compounds to treat benign prostatic hyperplasia. International Patent Application, No. WO94/10989, May 26, 1994.
75. Yamada, S.; Suzuki, M.; Kato, Y.; Kimura, R.; Mori, R.; Matsumoto, K.; Maruyama, M.; Kawabe, K. Binding characteristics of naftopidil and ai-adrenoceptor antagonists to prostatic a-adrenoceptors in benign prostatic hypertrophy. Life Sci. 1991, 50, 127-135.
76. Muramatsu, L; Yamanaka, K.; Kigoshi, S. Pharmacological profile of the novel a-adrenoceptor antagonist KT-611 (naftopidil). Jpn. J. Pharmacol. 1991, 55, 391-398.
77. Hieble, J. P.; Ruffolo, R. R., Jr.; Sulpizio, A. C.; Naselsky, D. P.; Conway, T. M.; Ellis, C.; Swift, A. M.; Ganguly, S.; Bergsma, D. J. Functional subclassification of the a2-adrenoceptors. Pharmacol. Commun. 1995, 6, 91-97.
78. Yamanaka, N.; Yamaguchi, O.; Kameoka, H.; Fukaya, Y.; Yokota, T.; Shiraiwa, Y. Effect of KT-611 (naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction. Acta Urol. Jpn. 1991, 37, 1759-1772.
79. Aubry, M. L.; Davey, M. J.; Petch, B. UK-52, 046, a novel ai- adrenoceptor antagonist with antidysrhythmic activity. Br. J. Pharmacol. 1988, 95, 752.
80. Marshall, I.; Burt, R. P.; Anderson, P. O.; Chappie, C. R.; Greengrass, P. M.; Johnson, G. L.; Wyllie, M. G. Human aic- adrenoceptor: Functional characterization in prostate. Br. J. Pharmacol. 1992, 107, 327P.
81. Burt, R. P.; Chappie, C. R.; Marshall, I. Functional identification of an au-adrenoceptor in rat epididymal vas deferens and an aiB-adrenoceptor in rat spleen. Br. J. Pharmacol. 1992, 107, 324.
82. Chess-Williams, R.; Jackson, A. H. Receptor and tissue dependent effects of abanoquil (UK 52046). Br. J. Pharmacol. 1993, 108, 115.
83. Angel, L; Schoemaker, H.; Arbilla, S.; Galzin, A. M.; Berry, C.; Niddam, R.; Pimoule, C.; Servin, M.; Wick, A.; Langer, S. Z. SL 84. 0418: a novel, potent and selective alpha-2 adrenoceptor antagonist: in vitro pharmacological profile. J. Pharmacol. Exp. Ther. 1992, 263, 137.
84. Angel, L; Grosset, A.; Perrault, G.; Schoemaker, H.; Langer, S. Z. In vivo pharmacological profile of SL 84. 0418, a new selective, peripherally active a2-adrenoceptor antagonist. Eur. J. Pharmacol. 1993, 234, 137.
85. Jonas, J.-C.; Plant, T. D.; Angel, I.; Langer, S. Z.; Henquin, J.-H. In vitro stimulation of insulin release of SL 84. 0418, a new a2-adrenoceptor antagonist. Eur. J. Pharmacol. 1994, 254, 27-33.
86. Hulbron, G.; Angel, I.; Oblin, A.; Friedman, J.; Langer, S. Z. Antihyperglycaemic effects of the new alpha-2 antagonist SL 84. 0418 in the primate (Macaca fascicularis) in comparison with idazoxan. Eur. J. Pharmacol. 1990, 183, 995-996.
87. Pimoule, C.; Graham, D.; Arbilla, S.; Langer, S. Z. Characterization of human (X2-adrenergic receptors stably expressed in transfected Chinese hamster ovary cell-lines. Br. J. Pharmacol. 1992, 107, 378P.
88. Abou-Mohamed, G.; Caldwell, R. W.; Carrier, G. O.; Elmazar, M. M.; Tuttle, R. R. Interactions of a novel catecholamine, Gp- 2-128, with adrenoceptors. J. Cardiovasc. Pharmacol. 1994, 23, 492-500.
89. Chiarino, D.; Fantucci, M.; Carenzi, A.; Della Bella, D.; Frigeni, V.; Sala, R. New isoxazole derivatives with a potent and selective β-adrenergic activity. Il Farmaco 1985, 41, 440-453.
90. Pauwels, P. J.; Gommeren, W.; Van Lommen, G.; Janssen, P. A. J.; Leysen, J. E. The receptor binding profile of the new antihypertensive agent nebivolol and its stereisomers compared with various /S-adrenergic blockers. Mol. Pharmacol. 1988, 34, 843-851.
91. Van de Water, A.; Janssens, W.; Van Neuten, J.; Xhonneux, R.; DeCree, J.; Verhagen, H.; Reneman, R. S.; Janssen, P. A. J. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective /?i-adrenergic antagonist. J. Cardiovasc. Pharmacol. 1988, 11, 552-563.
92. Lacourciere, Y.; Poirier, L.; Lefebvre, J.; Archambault, F.; Cleroux, J. Comparative assessment of antihypertensive efficacy of DL-nebivolol and D-nebivoIol in patients with confirmed mild to moderate hypertension. J. Cardiovasc. Pharmacol. 1995, 25, 619-624.
93. Heimburger, M.; Monterò, M. J.; Fougères, V.; Beslot, F.; Davy, M.; Midol-Monnet, M.; Cohen, Y. Presynaptic β-adrenoceptors in rat atria: evidence for the presence of stereoselective ßi- adrenoceptors. Br. J. Pharmacol. 1989, 98, 211-217.
94. Borges, N.; Martel, F.; Branco, D.; Osswald, W. Effects of nebivolol stereoisomers on the action of adrenaline on blood pressure, heart rate and blood levels of noradrenaline and DOPEG. J. Auton. Pharmacol. 1992, 12, 429-435.
95. Ruffolo, R. R., Jr.; Yaden, E-L.; Waddell, J. E. Stereochemical requirements of alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 1982, 222, 645-651.
96. Patii, P. N.; LaPidus, J. B.; Tye, A. Steric aspects of adrenergic drugs. J. Pharm. Sci. 1970, 59 (9), 1205-1234.
97. Triggle, D. J. Adrenergics: catecholamines and related agents. In Burger’s Medicinal Chemistry, Wolff, M. E., Ed.; John Wiley & Sons: New York, 1981; pp 225-283.
98. Easson, L. H.; Stedman, E. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem. J. 1933, 27, 1257-1266.
99. Beckett, A. H. Stereochemical factors in biological activity. Arzneim-Forsch 1959, 1, 451-455.
100. Ruffolo, R. R., Jr.; Waddell, J. E. Stereochemical requirements of a. 2-adrenergic receptors for a-methyl substituted phenethylamines. Life Sci. 1982, 31, 2999-3007.
101. Ruffolo, R. R., Jr.; Goldberg, M. R.; Morgan, E. L. Interactions of epinephrine, norepinephrine, dopamine and their corresponding a-methyl-substituted derivatives with alpha- and beta-adrenoceptors in the pithed rat. J. Pharmacol. Exp. Ther. 1984, 230, 595-599.
102. Ruffolo, R. R., Jr.; Nichols, A. J.; Stadel, J. M.; Hieble, J. P. Structure and function of a-adrenoceptors. Pharmacol. Rev. 1991, 43, 475-505.
103. Patii, P. N.; LaPidus, J. B.; Campbell, D.; Tye, A. Steric aspects of adrenergic drugs. II. Effects of DL-isomers and desoxy derivatives on the reserpine-pretreated vas deferens. J. Pharmacol. Exp. Ther. 1967, 155, 13-23.
104. Kaiser, C.; Colella, D. F.; Schwartz, M. S.; Garvey, E.; Wardell, J. R. Adrenergic agents. 1. Synthesis and potential β-adrenergic agonist activity of some catecholamine analogs bearing a substituted amino functionality in the meta position. J. Med. Chem. 1974, 17, 49-56.
105. Kaiser, C.; Schwartz, M. S.; Colella, D. F.; Wardell, J. R. Adrenergic agents. 3. Synthesis and adrenergic activity of some catecholamine analogs bearing a substituted sulfonyl or sulfon- ylalkyl group in the meta position. J. Med. Chem. 1975, 18, 674-683.
106. Baltzly, R.; Mehta, N. B. N-sec and N-t-alkyl derivatives of methoxamine and related compounds. J. Med. Chem. 1968, 11, 833-844.
107. Daly, J. W.; Creveling, C. R.; Witkop, B. The chemorelease of norepinephrine from mouse hearts. Structure activity relationships. I. Sympathomimetic and related amines. J. Med. Chem. 1966, 9, 273-280.
108. Ruffolo, R. R., Jr.; Dillard, R. D.; Rosing, E. L.; Waddell, J. E. Receptor interactions of imidazolines. II. Affinities and effica-cies of hydroxy-substituted tolazoline derivatives in rat aorta. J. Pharmacol. Exp. Ther. 1979, 211, 74-79.
109. Ruffolo, R. R., Jr.; Rice, P. J.; Patii, P. N.; Hamada, A.; Miller, D. D. Differences in the applicability of the Easson-Stedman hypothesis of the ai- and (X2-adrenergic effects of phenethylamines and imidazolines. Eur. J. Pharmacol. 1983, 86, 471-475.
110. Ruffolo, R. R., Jr.; Patii, P. N.; Miller, D. D. Adrenoceptor- mediated effects of optically active catecholimidazoline in pithed rat. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1983, 323, 221-227.
111. Miller, D. D.; Hamaga, A.; Craig, E. C.; Christoph, G. G.; Galiucci, J. C.; Rice, P. J.; Banning, J. W.; Patii, P. N. Optically active catecholimidazolines: A study of steric interactions at alpha-adrenoceptors. J. Med. Chem. 1983, 26, 957-963.
112. Kohli, J. D.; Volkman, P. H.; Goldberg, L. I.; Cannon, J. G. Conformational requirements for vascular a-adrenergic activity. Proc. Soc. Exp. Biol. Med. 1978, 158, 28-31.
113. Nimit, Y.; Cantacuzene, D.; Kirk, K L.; Creveling, C. R.; Daly, J. W. The binding of fluorocatecholamines to adrenergic and dopaminergic receptors in rat brain membranes. Life Sci. 1980, 27, 1577-1585.
114. Kaiser, C.; Colella, D. F.; Pavloff, A. M.; Wardell, J. R. Adrenergic agents. 2. Synthesis and potential adrenergic agonist activity of some ring-chlorinated relatives of isoproterenol. J. Med. Chem. 1974, 17, 1071-1076.
115. Volkman, P. H.; Kohli, J. D.; Goldberg, L. I.; Cannon, J. G.; Lee, T. Conformational requirements for dopamine-induced vasodilation. Proc. Natl. Acad. Sci. U. SA. 1977, 74, 3602-3606.
116. Pullman, B.; Coubelis, J. L.; Courriere, P. Quantum mechanical study of the conformational properties of phenethylamines of biochemical and medicinal interest. J. Med. Chem. 1972, 15, 17-23.
117. Hieble, J. P.; Pendelton, R. G. Effects of ring substitution of the pre- and postjunctional alpha-adrenergic activity of arylimi- noimidazolidines. Naunyn-Schmeideberg’s Arch. Pharmacol. 1979, 309, 217-224.
118. 13C nuclear magnetic resonance studies on the tautomerism, geometrical isomerism, and conformation of some cyclic amidines, guanidines, and related systems. J. Am. Chem. Soc. 1975, 97, 2811.
119. De Jong, A. P.; van Dam, H. Ultraviolet photoelectron spectroscopy of cyclic amidines. 2. Electronic structure of clonidine and some related 2-(phenylimino) imidazolidines with alpha-adrenergic activity. J. Med. Chem. 1980, 23, 889-895.
120. Timmermans, P. B. M. W. M.; van Zwieten, P. A. Influence of structural changes in the imidazolidine ring of clonidine on hypotensive activity. Pharmacology 1978, 16, 106-114.
121. Yu, S.; Ko, F.; Chueh, S.; Chen, J.; Chen, S.; Chen, C.; Teng, C. Effects of dicentrine, a novel ai-adrenoceptor antagonist, on human hyperplastic prostates. Eur. J. Pharmacol. 1994, 252, 29-34.
122. Morrison, G. A. Conformational analysis of some alkaloids. Forsch. Chem. Org. Naturstoffe 1967, 25, 269.
123. Lambert, G. A.; Lang, W. J.; Friedman, E.; Meller, E.; Gershon, S. Pharmacological and biochemical properties of isomeric yohimbine alkaloids. Eur. J. Pharmacol. 1978, 49, 39-48.
124. Weitzell, R.; Tanaka, T.; Starke, K Pre- and postsynaptic effects of yohimbine stereoisomers on noradrenergic transmission in the pulmonary artery of the rabbit. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1979, 308, 127-136.
125. McGrath, J. C. a-Adrenoceptor antagonism by apoyohimbine and some observations on the pharmacology of a-adrenoceptors in the rat anococcygeus and vas deferens. Br. J. Pharmacol. 1984, 82, 769-781.
126. Demichel, P.; Roquebert, J. Effects of raubasine stereoisomers on pre- and postsynaptic a-adrenoceptors in the rat vas deferens. Br. J. Pharmacol. 1984, 83, 505-510.
127. Roquebert, J. Selectivity of raubasine stereoisomers for ai- and a2-adrenoceptors in the rat. Arch. Int. Pharmacodyn. 1986, 282, 252-261.
128. Horiuchi, H.; Yano, S.; Watanabe, K; Yamanaka, E.; Aimi, N.; Sakai, S. Structure specificities of yohimbine and indoloquino- lizidine derivatives in blocking alpha-adrenoceptor and calcium channel. Chem. Path. Pharmacol. 1988, 59, 407-410.
129. Shepperson, N. B.; Duval, N.; Massingham, R.; Langer, S. Z. Pre- and postsynaptic alpha-adrenoceptor selectivity studies with yohimbine and its two diastereoisomers rauwolscine and corynanthine in the anesthetized dog. J. Biol. Chem. 1981, 256, 5280-5286.
130. Ruffolo, R. R., Jr.; Messick, K; Homg, J. S. Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with a- and adrenoceptors in vitro. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1984, 326, 317-326.
131. Malta, E.; McPherson, G. A.; Râper, C. Selective ft-adrenoceptor agonists - fact or fiction? Trends Pharmacol. Sci. 1985, 6, 400-403.
132. Ruffolo, R. R., Jr.; Spradlin, T. A.; Pollock, G. D.; Waddell, J. E.; Murphy, P. J. Alpha- and òeto-adrenergic effects of the stereoisomers of dobutamine. J. Pharmacol. Exp. Ther. 1981, 219, 447-452.
133. Ruffolo, R. R., Jr.; Messick, K. Effects of dopamine, (±)- and (-)- enantiomers of dobutamine on cardiac function in pithed rats. J. Pharmacol. Exp. Ther. 1985, 235, 558-565.
134. Blackburn, C. G.; Byrne, L. J.; Cullum, V. A.; Farmer, J. B.; Levy, G. P. The pharmacology of 5-(2-t-butylamino-1-hydroxyethyl) salicyamide (AH 3474), a β-adrenoceptor blocking agent. J. Pharm. Pharmacol. 1969, 21, 488-497.
135. Sybertz, E. J.; Sabin, C. S.; Pula, K. K.; van Der Vliet, G.; Glennon, J.; Gold, E. H.; Baum, T. Alpha- and beta-adrenoceptor blocking properties of labetalol and its R, R-isomer, SCH 19927. J. Pharmacol. Exp. Ther. 1981, 218, 435-443.
136. Brittain, R. T.; Drew, G. M.; Levy, G. P. The a- and β-adrenoceptor blocking potencies of labetolol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br. J. Pharmacol. 1982, 77, 105-114.
137. Baum, T.; Watkins, R. W.; Sybertz, E. J.; Vemularalli, S.; Pula, K. K.; Eynon, E.; Nelson, S.; van Der Vliet, G.; Glennon, J.; Moran, R. M. Antihypertensive and hemodynamic actions of SCH 19927, the R, R-isomer of labetolol. J. Pharmacol. Exp. Ther. 1981, 218, 444-452.
138. Watkins, R. W.; Sybertz, E. J.; Pula, K.; Rivelli, M. Effects of the antihypertensive dilevalol on large artery compliance in anesthetized dogs. J. Cardiovasc. Pharmacol. 1987, 10 (Suppl. 11), S58-S63.
139. Riva, E.; Mennini, T.; Latini, R. The a- and β-adrenoceptor blocking activities of labetolol ant its RR-SR (50: 50) stereoisomers. Br. J. Pharmacol. 1992, 104, 823-838.
140. Nichols, A. J.; Sulpizio, A. C.; Ashton, D. J.; Hieble, J. P.; Ruffolo, R. R., Jr. The interaction of the enantiomers of carvedilol with ai- and /li-adrenoceptors. Chirality 1989, 1, 265-270.
141. 2+ channels and to a subtype of ai-adrenoceptors. Eur. J. Pharmacol. 1989, 172, 131-145.
142. Schwinn, D. A.; Johnson, G. I.; Page, S. O.; Mosley, M. J.; Wilson, K. H.; Worman, N. P.; Campbell, S.; Fidock, M. D.; Furness, L. M.; Parry-Smith, D. J.; Peter, B.; Baily, D. S. Cloning and pharmacologic characterization of human di-adrenergic receptors: sequence corrections and direct comparisons with other species homologues. J. Pharmacol. Exp. Ther. 1995, 272, 134-142.
143. Hieble, J. P.; Ruffolo, R. R., Jr. Therapeutic applications of agents interacting with a-adrenoceptors. In a-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology, Ruffolo, R. R., Jr., Ed; Karger: Basel, 1991; Vol. 8, pp 180-220.
144. Ford, A. P. D. W.; Williams, T. J.; Blue, D. R.; Clarke, D. E. diAdrenoceptor classification: Sharpening Occam’s razor. Trends Pharmacol. Sci. 1994, 15, 167-170.
145. Muramatsu, I.; Ohmura, T.; Hashimoto, S.; Oshita, M. Functional subclassification of vascular ai-adrenoceptors. Pharmacol. Commun. 1995, 6, 23-28.
146. Saussy, D. L.; Goetz, A. S.; King, H. K.; True, T. A. BMY 7378 is a selective antagonist of am-adrenoceptors: Further evidence that vascular oq-adrenoceptors are of the am-subtype. Can. J. Physiol. Pharmacol. 1994, 72 (Suppl. 1), 323.
147. Buckner, S. A.; Oheim, K.; Morse, P.; Knepper, S.; Hancock, A. A.; Kerwin, J. F. J. Functional and radioligand binding evidence for an am-adrenoceptor subtype mediating contraction in the rat aorta. FASEB J. 1995, 9, A105.
148. Price, D. T.; Lefkowitz, R. J.; Caron, M. G.; Berkowitz, D.; Schwinn, D. A. Localization of mRNA for three distinct ai- adrenergic receptor subtypes in human tissues: Implications for human a-adrenergic physiology. Mol. Pharmacol. 1994, 45, 171-175.
149. Hirasawa, A.; Horie, K.; Tanaka, T.; Takagaki, K.; Murai, M.; Yano, J.; Tsujimoto, G. Cloning, functional expression and tissue distribution of human cDNA for the am-adrenergic receptor. Biochem. Biophys. Res. Commun. 1993, 195, 902-909.
150. Blue, D. R.; Ford, A. P. D. W.; Kava, M. S.; Pfister, J. R.; Vimont, R. L.; Zhu, Q. M.; Clarke, D. E. A rat model for assessing cti- adrenoceptor subtype selectivity of orally administered drugs: Studies with RS 17053. FASEB J. 1995, 9, A105.
151. Ekenwall, L.; Lindblad, L. E.; Norbeck, O.; Etzell, B. a-Adrenoceptors and cold-induced vasoconstriction in human finger skin. Am. J. Physiol. 1988, 24, H1000-H1003.
152. Coffman, J. D.; Cohen, R. A. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur. J. Clin. Invest. 1988, 18, 309-313.
153. Willette, R. N.; Hieble, J. P.; Sauermelch, C. F. The role of alpha adrenoceptor subtypes in sympathetic control of the acral- cutaneous microcirculation. J. Pharmacol. Exp. Ther. 1991, 256, 599-605.
154. Nielsen, H.; Mortensen, F. V.; Mulvany, M. J. Differential distribution of postjunctional a. 2-adrenoceptors in human omental small arteries. J. Cardiovasc. Pharmacol. 1990, 16, 34-40.
155. Flavahan, N. A.; Rimeli, T. J.; Cooke, J. P.; Vanhoutte, P. M. Characterization of postjunctional alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-release norepinephrine in the canine saphenous vein. J. Pharmacol. Exp. Ther. 1984, 230, 699-705.
156. Docherty, J. R. The use of the human saphenous vein in pharmacology. Trends Pharmacol. Sci. 1987, 8, 358-361.
157. Timmermans, P. B. M. V. M.; van Zweiten, P. A. The postsynaptic ci2-adrenoceptor. J. Auton. Pharmacol. 1981, 1, 171-183.
158. Ruffolo, R. R., Jr.; Morgan, E. L.; Messick, K. Possible relationship between receptor reserve and the differential antagonism of (Xi- and o adrenoceptor mediated pressor responses by calcium channel antagonists in pithed rat. J. Pharmacol. Exp. Ther. 1984, 230, 587-594.
159. Berkowitz, D. E.; Price, D. T.; Bello, E. A.; Page, S. O.; Schwinn, D. A. Localization of messenger RNA for three distinct ci2- adrenergic receptor subtypes in human tissues. Anesthesiology 1994, 81, 1235-1244.
160. Craig, D.; Iacolina, M.; Forray, C. (X2-Adrenoceptors mediate norepinephrine-induced contraction of rat caudal artery. FASEB J. 1995, 9, A106.
161. McCafferty, J. P.; Hieble, J. P.; Roesler, J. M.; Kopaciewicz, L. J. Activation of both vascular alpha-adrenoceptor subtypes is required for maintenance of blood pressure in DOCA-salt hypertensive rats. Fed. Proc. 1982, 41, 1668.
162. Sawyer, R.; Warnock, P.; Docherty, J. R. Role of vascular o adrenoceptors as targets for circulating catecholamines in the maintenance of blood pressure in anaesthetized spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 1985, 7, 809-812.
163. Hansson, L. Antipathological potential of β-blockers. J. Cardiovasc. Pharmacol. 1989, 14 (Suppl. 7), S1-S3.
164. Conolly, M. E.; Greenacre, J. K. The lymphocyte β-adrenoceptor in normal subjects and patients with bronchil asthma: effect of different forms of treatment. J. Clin. Invest. 1976, 58, 1307-1316.
165. Grove, A.; Lipworth, B. J. Tolerance with a adrenoceptor agonists: time for reappraisal. Br. J. Clin. Pharmacol. 1995, 39, 109-118.
166. Hieble, J. P.; Sulpizio, A. C.; Goldstein, R. S. Determination of the a-adrenoceptor subtype involved in modulation of the response to glucose challenge in the rat. Pharm. Commun. 1992, 1, 59-69.
167. Giugliano, D.; Torella, R.; Varricchio, M.; Sgambato, S. Samatostatin and insulin secretion in man. I. The effect of phen- tolamine. Pharmacol. Res. Commun. 1980, 12, 57-66.
168. Elliott, H. L.; Jones, C. R.; Vincent, J.; Lawrie, C. B.; Reid, J. L. The afp/ia-adrenoceptor antagonist properties of idazoxan in normal subjects. Clin. Pharmacol. Ther. 1984, 36, 190-196.
169. Robertson, R. P.; Halter, J. B.; Porte, D. A role of alpha- adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J. Clin. Invest. 1976, 57, 791-795.
170. Schultz, A.; Hasselblatt, A. Dual action of clonidine on insulin release: Suppression, but stimulation when a. 2-adrenoceptors are blocked. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1989, 340, 712-714.
171. Schultz, A.; Hasselblatt, A. An insulin releasing property of imidazoline derivatives is not limited to compounds that block a-adrenoceptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1989, 340, 321-327
172. Ortiz-Alonso, F. J.; Herman, W. H.; Gertz, B. J.; Williams, V. C.; Smith, M. J., Halter, J. B. Effect of an oral a2-adrenergic blocker (MK-912) on pancreatic islet function in non-insulindependent diabetes mellitus. Metabolism 1991, 40, 1160-1167.
173. Kawazu, S.; Suzuki, M.; Negishi, K.; Watanabe, T.; Ishii, J. Studies of midazlizole (DG-5128), a new type of oral hypogly-cemic drug in healthy subjects. Diabetes 1987, 36, 216-220.
174. Kawazu, S.; Suzuki, M.; Negishi, K; Ishii, J.; Sando, H.; Katagiri, H.; Kanazawa, Y.; Yamanouchi, S.; Akanuma, Y.; Kajinuma, H; Suzuki, K.; Watanabe, K.; Itoh, T.; Kobayashi, T.; Kosaka, K. Initial phase II clinical studies on midaglizole (DG-5128), a new hypoglycemic agent. Diabetes 1987, 36, 221-226.
175. Bergougnan, L.; Rossenzweig, P.; Duchier, J.; Cournot, A.; Berlin, I.; Morselli, P. L. SL 84. 0418: Clinical and cardiovascular tolerance in healthy young volunteers of a new alpha-2 antagonist with anti-hyperglycaemic properties. Eur. J. Pharmacol. 1990, 183, 1015-1016.
176. Connacher, A. A.; Jung, R. T.; Mitchell, P. E. G. Weight loss in obese subjects given BRL 26830A, a new atypical β-adrenoceptor agonist. Br. Med. J. 1988, 296, 1217-1220.
177. Sennitt, M. V.; Arch, J. R. S.; Levy, A. L.; Simson, D. L.; Smith, S. Q.; Cawthome, M. A. Anti-hyperglycaemic action of BRL 26830, a novel β-adrenoceptor agonist, in mice and rats. Biochem. Pharmacol. 1985, 34, 1279-1285.
178. Smith, S. A.; Levy, A. L.; Sennitt, M. V.; Simson, D. L.; Cawthome, M. A. Effects of BRL 26830, a novel β-adrenoceptor agonist, on glucose tolerance, insulin sensitivity and glucose turnover in Zucker (fa/fa) rats. Biochem. Pharmacol. 1985, 34, 2425-2429.
179. Raz, S.; Zeigler, M.; Caine, M. Pharmacological receptors in the prostate. Br. J. Urol. 1973, 45, 663-667